<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29898148</article-id><article-id pub-id-type="pmc">5985845</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Association of Oscillatory Ventilation during Cardiopulmonary Test to
Clinical and Functional Variables of Chronic Heart Failure
Patients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reis</surname><given-names>Hugo Valverde</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>PT, MSc</role></contrib><contrib contrib-type="author"><name><surname>Sperandio</surname><given-names>Priscila Abreu</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>PT, MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Correa</surname><given-names>Clynton Louren&#x000e7;o</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>PT, MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Guizilini</surname><given-names>Solange</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>PT, MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Neder</surname><given-names>Jos&#x000e9; Alberto</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Borghi-Silva</surname><given-names>Audrey</given-names></name><xref ref-type="aff" rid="aff4">4</xref><role>PT, MSc, PhD</role></contrib><contrib contrib-type="author"><name><surname>Reis</surname><given-names>Michel Silva</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>PT, MSc, PhD</role></contrib></contrib-group><aff id="aff1"><label>1</label> Research Group in Cardiorespiratory Rehabilitation
(GECARE) and Department of Physical Therapy, Faculdade de Medicina, Universidade
Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil.</aff><aff id="aff2"><label>2</label> Pulmonary Function and Clinical Exercise Physiology Unit
(SEFICE), Respiratory Division, Department of Medicine, Escola Paulista de Medicina,
Universidade Federal de S&#x000e3;o Paulo (EPM-UNIFESP), S&#x000e3;o Paulo, SP,
Brazil.</aff><aff id="aff3"><label>3</label> Respiratory Division, Department of Physiotherapy,
Universidade Federal de S&#x000e3;o Paulo (UNIFESP), S&#x000e3;o Paulo, Brazil.</aff><aff id="aff4"><label>4</label> Laboratory of Cardiopulmonary Physical Therapy (LACAP),
Department of Physical Therapy, Universidade Federal de S&#x000e3;o Carlos (UFSCAR),
S&#x000e3;o Carlos, SP, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: Michel Silva Reis, Universidade Federal do
Rio de Janeiro, Departamento de Fisioterapia, Faculdade de Medicina, Rua Prof.
Rodolpho Paulo Rocco, s/n, 8&#x000ba; andar ala E, sala 3 (8E-03), Ilha do Fund&#x000e3;o
- Rio de Janeiro, RJ, Brazil - Zip code: 21941-913. E-mail:
<email>msreis@hucff.ufrj.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2018</year></pub-date><volume>33</volume><issue>2</issue><fpage>176</fpage><lpage>182</lpage><history><date date-type="received"><day>02</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The aim of this study is to characterize the presence of exercise oscillatory
ventilation (EOV) and to relate it with other cardiopulmonary exercise test
(CET) responses and clinical variables.</p></sec><sec><title>Methods</title><p>Forty-six male patients (age: 53.1&#x000b1;13.6 years old; left ventricular
ejection fraction [LVEF]: 30&#x000b1;8%) with heart failure were recruited to
perform a maximal CET and to correlate the CET responses with clinical
variables. The EOV was obtained according to Leite et al. criteria and
VE/VCO<sub>2</sub> &#x0003e; 34 and peak VO<sub>2</sub> &#x0003c; 14 ml/kg/min
were used to assess patients' severity.</p></sec><sec><title>Results</title><p>The EOV was observed in 16 of 24 patients who performed the CET, as well as
VE/VCO<sub>2</sub> &#x0003e; 34 and peak VO<sub>2</sub> &#x0003c; 14 ml/kg/min in
14 and 10 patients, respectively. There was no difference in clinical and
CET variables of the patients who presented EOV in CET when compared to
non-EOV patients. Also, there was no difference in CET and clinical
variables when comparing patients who presented EOV and had a
VE/VCO<sub>2</sub> slope &#x0003e; 34 to patients who just had one of these
responses either.</p></sec><sec><title>Conclusion</title><p>The present study showed that there was an incidence of patients with EOV and
lower peak VO<sub>2</sub> and higher VE/VCO<sub>2</sub> slope values, but
they showed no difference on other prognostic variables. As well, there was
no influence of the presence of EOV on other parameters of CET in this
population, suggesting that this variable may be an independent marker of
worst prognosis in HF patients.</p></sec></abstract><kwd-group><kwd>Heart Failure</kwd><kwd>Exercise Test</kwd><kwd>Respiratory Mechanics</kwd><kwd>Physical Exertion</kwd></kwd-group></article-meta></front><body><table-wrap id="t3" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="43%" span="1"/><col width="4%" span="1"/><col width="5%" span="1"/><col width="43%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" colspan="2" style="background-color:#e6e7e8" rowspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Angiotensin-converting
enzyme</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AT</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Anaerobic threshold</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">NYHA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= New York Heart
Association</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PETCO<sub>2</sub></td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= End-tidal partial
pressure of carbon dioxide</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BTPS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body temperature
pressure standard</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PETO<sub>2</sub></td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= End-tidal partial
pressure of oxygen</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CET</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary exercise
test</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RER</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Respiratory exchange
ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CHF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic heart
failure</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">RR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Respiratory rate</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CMDC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Carbon monoxide
diffusion capacity</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SpO<sub>2</sub></td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Blood oxygen
saturation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EOV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Exercise oscillatory
ventilation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SVC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Slow vital capacity</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FEV<sub>1</sub></td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Forced expiratory volume
in 1 second</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VCO<sub>2</sub></td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Carbon dioxide
production</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Flow-volume</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Ventilation
production</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">FVC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Forced vital
capacity</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">VO<sub>2</sub></td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Oxygen consumption</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Heart rate</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Cardiovascular ischemic events are the leading cause of chronic heart failure (CHF),
which is a syndrome that is generally characterized by the classic left ventricular
systolic impairment with consequent muscular peripheral
dysfunction<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup> caused by not only the low cardiac output, but also
by medications, oxidative stress, and chronic hypoxemia, among
others<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. An important outcome of this peripheral muscular
dysfunction is the reduced functional capacity, negatively affecting the patients'
autonomy and consequently their quality of life<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>.</p><p>Many parameters are known as independent markers of severity and predictors of
morbidity and mortality in this group of patients. The maximal inspiratory pressure
has been shown as an independent variable to quantify the survival rate of these
patients<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup> because it may reflect the inspiratory muscle
weakness, usually witnessed in them. Furthermore, the handgrip strength has also
been reported as an isolated parameter of CHF severity<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. In this context, we may
highlight the significance of the cardiopulmonary exercise test (CET). It is a
useful tool that induce physiological responses in exercise conditions that might
not appear at rest conditions.</p><p>From the parameters obtained in the CET, many of them have been described as
negatively influenced by CHF progression. It is quite well known that patients with
CHF present low functional status and exercise capacity, with reduced peak oxygen
consumption (VO<sub>2</sub>)<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>. Another powerful CET variable that may reflect the
severity of these patients and, more specifically, the pulmonary congestion is the
ventilation production (VE)/ carbon dioxide production (VCO<sub>2</sub>) slope,
which shows the ventilatory inefficiency, mainly in those who have values &#x0003e; 34,
strongly characterizing pulmonary congestion<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Also, the presence of oscillatory ventilation
in rest or during exercise is being considered as an important variable with
prognostic value of CET<sup>[<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Besides this importance, there is still no
standardization for obtaining and interpreting exercise oscillatory ventilation
(EOV)<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p><p>Therefore, the aim of the present study is to characterize the presence of EOV and to
relate it with other clinical variables in patients with CHF.</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Study Design</title><p>This is an observational and transversal study with convenience sample.</p></sec><sec><title>Patients</title><p>Forty-six men with CHF were recruited by clinical assessment. Inclusion criteria
were previous history of stable symptomatic CHF due to left ventricular systolic
dysfunction, documented for at least six months (left ventricular ejection
fraction [LVEF]: &#x0003c; 45%), New York Heart Association (NYHA) class between
II-III, and clinical stability for at least three months. Patients were excluded
from study if they had clinical and/or functional evidence of obstructive
pulmonary disease (forced expiratory volume in 1 second [FEV<sub>1</sub>]/forced
vital capacity [FVC] &#x0003c; 70% in pulmonary test)<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>, exercise-induced
asthma, unstable angina or significant cardiac arrhythmias, and myocardial
infarction within the previous six months; also, none of the subjects were
tobacco users, alcohol dependents, or users of addicting drugs. No patient had
been submitted to cardiovascular rehabilitation. All subjects presented the same
clinical management, optimized medications, and were clinically stable. The
eligible participants signed a written informed consent and the study protocol
was approved by the Ethics Committee of Institution (protocol 238/06 and
protocol 970.098).</p></sec><sec><title>Experimental Procedure</title><p>The research was performed in an air-conditioned laboratory, with temperature
between 22&#x000ba;C and 24&#x000ba;C, and relative humidity between 50 and 60%, always in the
same period of the day (between 8 am and 12 pm). In the day before the test,
patients were warned to avoid the intake of stimulating drinks, not to perform
physical activity, and to have light meals and at least 8 hours of sleep. First,
the volunteers were familiarized with the experimental set and involved
researchers. Before the test begun, the patients were examined to verify if the
recommendations were followed. Then, the systolic and diastolic arterial blood
pressure and the peripheral oxygen saturation were measured, and it was
performed auscultation.</p></sec><sec><title>Pulmonary Function</title><p>Pulmonary function tests, measuring slow vital capacity (SVC), FVC,
FEV<sub>1</sub>, and FEV<sub>1</sub>/FVC ratio, were carried out using the
CardiO<sub>2</sub> System (Medical Graphics Corporation, St. Paul, MO, USA).
For comparative purposes, reference values from Knudson et
al.<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>, expressed in body temperature pressure
standard (BTPS) conditions, were used. Carbon monoxide diffusion capacity (CMDC)
was assessed by simple respiration model and static volumes were assessed by
whole-body plethysmography. Technical procedures and the acceptability and
reproducibility criteria were defined according to norms recommended by the
American Thoracic Society<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p></sec><sec><title>Ventilatory and Metabolic Variables During CET</title><p>Ventilatory and metabolic variables were obtained by a computer connected to an
ergospirometric measurement system (CardiO<sub>2</sub> System), using the Breeze
Suite 6 software package. Tidal volume was obtained by a Pitot pneumotachometer
connected to the CardiO<sub>2</sub> System and attached to a facial mask - which
was selected considering the volunteer's face size and providing an adequate fit
in order to avoid air leakage. The device presents in real time applied power
values (W) and pedaling speed (rpm), as well as VO<sub>2</sub>, VCO<sub>2</sub>,
minute ventilation (VE), heart rate (HR), and blood oxygen saturation
(SpO<sub>2</sub>). Ventilatory equivalent values (VE/VO<sub>2</sub> and
VE/VCO<sub>2</sub>), respiratory exchange ratio (RER), end-tidal partial
pressure of oxygen (P<sub>ET</sub>O<sub>2</sub>) and carbon dioxide
(P<sub>ET</sub>CO<sub>2</sub>), flow-volume (FV), and respiratory rate (RR)
were also calculated and registered. The power applied to the cycle ergometer
during exercise protocols was controlled by the system through an interface with
the bicycle.</p></sec><sec><title>Data Analysis</title><p>The following parameters were analyzed in CET variables:</p><sec><title>First Ventilatory Threshold (At) Obtained</title><p>Visual analysis of VO<sub>2</sub> and VCO<sub>2</sub> correlation curves,
VE/VO<sub>2</sub>, and P<sub>ET</sub>O<sub>2</sub> were graphically
represented in moving mean values each eight respiratory cycles.
Subsequently, three independent observers determined the anaerobic threshold
(AT) under the following situations: 1) V-slope: breaking point from
linearity in VO<sub>2</sub> and VCO<sub>2</sub> correlation curves; 2)
VE/VO<sub>2</sub>: nadir point of this ratio, ensuring that a systematic
increase occurs from it; and 3) P<sub>ET</sub>O<sub>2</sub>: nadir point of
this variable, from which a systematic increase begins. The CET data were
set from the beginning of the ventilatory and metabolic variables responses
to power output increments till the end of the exercise. Analysis of each
observer was performed in an independent manner, on a 15 inches monitor
(SyncMaster 550V, Samsung) connected to the MedGraphics software.</p></sec><sec><title>Exercise Oscillatory Ventilation (EOV)</title><p>The presence of periodic breathing was obtained by the analysis of
ventilation data, and it was confirmed if there were three consecutive
cycles with minimal average amplitude of 5 l in these data (peak value minus
the average of two in-between consecutive nadirs), as suggested by Leite et
al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>.</p></sec><sec><title>VE/VCO<sub>2</sub> slope</title><p>VE and VCO<sub>2</sub> data were analyzed from the beginning of the exercise
till peak. Data were input into spreadsheet software (Microsoft Excel) to
calculate VE/VCO<sub>2</sub> slope via least squares linear regression (y =
mx + b, m = slope).</p><p>VE/VCO<sub>2</sub> &#x0003e; 34 and peak VO<sub>2</sub> &#x0003c; 14 ml/kg/min were
used to assess patients' severity.</p></sec></sec><sec><title>Statistical Analyses</title><p>Statistical analyses were performed using the SigmaPlot version 11.0.0.007 (for
Windows(r)) with level of significance set at 0.05. Data were submitted to a
normality test (Shapiro-Wilk). As a normal distribution was observed, parametric
statistical tests were used. For intergroup comparisons, the t-Student pared
test was applied. Demographics, anthropometrics, and clinical data were
presented as means with standard deviation.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Forty-six male patients were recruited; 22 patients were excluded and 24 were
included in the present study (<xref ref-type="fig" rid="f1">Figure 1</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flowchart of the present study. CHF = chronic heart failure; CET =
cardiopulmonary exercise test.</p></caption><graphic xlink:href="rbccv-33-02-0176-g01"/></fig>
</p><p>
<xref ref-type="table" rid="t1">Table 1</xref> shows age and anthropometric and
clinical characteristics of these patients, as well as their functional status and
the CET variables with their prognostic thresholds. Body mass index (BMI) average
showed that most of the patients were overweight and they were in NYHA functional
class II and III. Among the 24 included patients, 16 presented EOV.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Anthropometrics, clinical and cardiopulmonary exercise test (CET) data of the
patients included in the present study.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="70%" span="1"/><col width="30%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="center" rowspan="1" colspan="1">(n=24)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">53.1&#x000b1;13.6</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="center" rowspan="1" colspan="1">169&#x000b1;7</td></tr><tr><td align="left" rowspan="1" colspan="1">Mass (kg)</td><td align="center" rowspan="1" colspan="1">76.27&#x000b1;12.83</td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">26.5&#x000b1;3.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Functional status</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;NYHA II/III</td><td align="center" rowspan="1" colspan="1">9/15</td></tr><tr><td align="left" rowspan="1" colspan="1">CET</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Peak VO<sub>2</sub> (ml/min)</td><td align="center" rowspan="1" colspan="1">1135.0&#x000b1;325.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Peak VO<sub>2</sub> (ml/kg/min)</td><td align="center" rowspan="1" colspan="1">15.1&#x000b1;4.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;AT VO<sub>2</sub> (l/min)</td><td align="center" rowspan="1" colspan="1">655.8&#x000b1;189.1</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;AT VO<sub>2</sub> (ml/kg/min)</td><td align="center" rowspan="1" colspan="1">8.7&#x000b1;2.5</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Peak P<sub>ET</sub>CO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">29.7&#x000b1;7.8</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;VE/VCO<sub>2</sub></td><td align="center" rowspan="1" colspan="1">40.1&#x000b1;15.7</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;EOV Yes/No</td><td align="center" rowspan="1" colspan="1">16/8</td></tr><tr><td align="left" rowspan="1" colspan="1">Prognostic values</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;VE/VCO<sub>2</sub> &#x0003e; 34 (n/%)</td><td align="center" rowspan="1" colspan="1">14/46</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;PeakVO<sub>2</sub> &#x0003c; 14 ml/kg/min (n/%)</td><td align="center" rowspan="1" colspan="1">10/25</td></tr><tr><td align="left" rowspan="1" colspan="1">Medications</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Diuretics (n)</td><td align="center" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Digitalics (n)</td><td align="center" rowspan="1" colspan="1">9</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;Beta-blockers (n)</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;ACE-inhibitors (n)</td><td align="center" rowspan="1" colspan="1">15</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Mean &#x000b1; standard deviation. ACE=angiotensin-converting enzyme;
AT=anaerobic threshold; BMI=body mass index; EOV=exercise oscillatory
ventilation; NYHA=New York Heart Association;
P<sub>ET</sub>CO<sub>2</sub>=end-tidal partial pressure of carbon
dioxide; VE/VCO<sub>2</sub>=ventilation/carbon dioxide production;
VO<sub>2</sub>=oxygen consumption</p></fn></table-wrap-foot></table-wrap><p>
<xref ref-type="fig" rid="f2">Figure 2</xref> shows the data obtained from patients
with EOV (EOV+) and patients who did not present EOV (EOV-) on incremental CET with
other parameters obtained from the CET, as well as their clinical variables and age.
There was no difference between EOV+ and EOV- groups.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Analysis of age, cardiopulmonary exercise test and clinical variables of
exercise oscillatory ventilation (EOV+) population and non-EOV (EOV-)
population. (A) Peak oxygen consumption (ml/kg/min). (B) Peak oxygen
consumption (ml/min). (C) Oxygen consumption (ml/kg/min) at anaerobic
threshold (AT). (D) Oxygen consumption at AT (ml/min). (E) VE/VCO2
slope. (F) Age. (G) Left ventricular ejection fraction (LVEF) (%). (H)
New York Heart Association (NYHA) functional class.</p></caption><graphic xlink:href="rbccv-33-02-0176-g02"/></fig>
</p><p>Also, there was no difference on age, clinical variables and parameters of the CET
data obtained from patients with EOV <italic>and</italic> VE/VCO<sub>2</sub> slope
&#x0003e; 34 when compared to patients with EOV <italic>or</italic> VE/VCO<sub>2</sub>
slope &#x0003e; 34, as shown on <xref ref-type="table" rid="t2">Table 2</xref>. Such
analysis was performed to verify if the patients who presented these two concomitant
responses had a more severe status than those who didn't.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Analysis of cardiopulmonary exercise test (CET) parameters of patients with
exercise oscillatory ventilation (EOV+) and VE/VCO<sub>2</sub> &#x0003e;34 or
just one of these variables.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">EOV (+) and VE/VCO<sub>2</sub> &#x0003e;34</th><th align="center" rowspan="1" colspan="1">EOV (+) or VE/VCO<sub>2</sub> &#x0003e; 34</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="center" rowspan="1" colspan="1">31.5&#x000b1;4.5</td><td align="center" rowspan="1" colspan="1">30&#x000b1;6.5</td><td align="center" rowspan="1" colspan="1">0.51</td></tr><tr><td align="left" rowspan="1" colspan="1">Peak VO<sub>2</sub> (ml/kg/min)</td><td align="center" rowspan="1" colspan="1">13.8&#x000b1;3.7</td><td align="center" rowspan="1" colspan="1">16.1&#x000b1;5.1</td><td align="center" rowspan="1" colspan="1">0.25</td></tr><tr><td align="left" rowspan="1" colspan="1">Peak VO<sub>2</sub> (ml/min)</td><td align="center" rowspan="1" colspan="1">1075.7&#x000b1;373.5</td><td align="center" rowspan="1" colspan="1">1199.0&#x000b1;349.9</td><td align="center" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">AT VO<sub>2</sub> (ml/kg/min)</td><td align="center" rowspan="1" colspan="1">8.3&#x000b1;2.3</td><td align="center" rowspan="1" colspan="1">9.4&#x000b1;3.1</td><td align="center" rowspan="1" colspan="1">0.39</td></tr><tr><td align="left" rowspan="1" colspan="1">AT VO<sub>2</sub> (ml/min)</td><td align="center" rowspan="1" colspan="1">648.1&#x000b1;205.7</td><td align="center" rowspan="1" colspan="1">704.1&#x000b1;222.9</td><td align="center" rowspan="1" colspan="1">0.57</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">55.2&#x000b1;13.3</td><td align="center" rowspan="1" colspan="1">52.1&#x000b1;14.8</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA</td><td align="center" rowspan="1" colspan="1">2.7&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">2.6&#x000b1;0.5</td><td align="center" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1">Peak P<sub>ET</sub>O<sub>2</sub> (mmHg)</td><td align="center" rowspan="1" colspan="1">109.1&#x000b1;4.3</td><td align="center" rowspan="1" colspan="1">104.9&#x000b1;7.4</td><td align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Peak P<sub>ET</sub>CO<sub>2</sub> (mmHg)</td><td align="center" rowspan="1" colspan="1">26.&#x000b1;3.7</td><td align="center" rowspan="1" colspan="1">31.&#x000b1;10.3</td><td align="center" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Peak workload (W)</td><td align="center" rowspan="1" colspan="1">84.9&#x000b1;27.6</td><td align="center" rowspan="1" colspan="1">91.3&#x000b1;31.0</td><td align="center" rowspan="1" colspan="1">0.64</td></tr><tr><td align="left" rowspan="1" colspan="1">HR (bpm)</td><td align="center" rowspan="1" colspan="1">123.5&#x000b1;27.0</td><td align="center" rowspan="1" colspan="1">122.5&#x000b1;19.8</td><td align="center" rowspan="1" colspan="1">0.92</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>Mean &#x000b1; standard deviation. <italic>P</italic> value &#x0003c; 0.05</p></fn><fn id="TFN3"><p>AT=anaerobic threshold; HR=heart rate; LVEF=left ventricle ejection
fraction; NYHA=New York Heart Association; PetCO<sub>2</sub>=end-tidal
partial pressure of carbon dioxide;
P<sub>ET</sub>O<sub>2</sub>=end-tidal partial pressure of oxygen;
VE/VCO<sub>2</sub>=ventilation/carbon dioxide production;
VO<sub>2</sub>=oxygen consumption</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>The present study's main findings are: (i) no difference between CET variables in
patients with EOV and non-EOV; (ii) the absence of difference on functional
variables between CHF patients with EOV <italic>and</italic> VE/VCO<sub>2</sub> &#x0003e;
34 and those with EOV <italic>or</italic> VE/VCO<sub>2</sub> &#x0003e; 34; iii) the
presence of EOV and peak VO<sub>2</sub> &#x0003c; 14 ml/kg/min in 25% of the patients, as
well as EOV and VE/VCO<sub>2</sub> &#x0003e; 34 in 46% of them.</p><p>Anthropometric data of CHF patients showed that they were overweight and that 15 of
the 24 evaluated patients were classified as NYHA functional class III. Furthermore,
they had a poor exercise performance on CET, which can be seen by the value of peak
VO<sub>2</sub> (15.1 ml/kg/min), presenting low peak workload values. The
literature shows that CHF patients exhibit a low peak VO<sub>2</sub>
<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup> as a
marker of exercise intolerance caused by many factors of this disease as the low
cardiac output, pulmonary congestion, and alterations of metabolism on peripheral
and ventilatory muscle fibers that lead to a muscular dysfunction with impact on
exercise tolerance. Peak VO<sub>2</sub> is also a prognostic variable of
CET<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r6" ref-type="bibr">6</xref>]</sup>.</p><p>Other CET variables showed similarities between our study and the literature,
specifically when it comes to the coexisting presence of EOV and other bad
prognostic variables, such as VE/VCO<sub>2</sub> &#x0003e; 34 and peak VO<sub>2</sub>
&#x0003c; 14 ml/kg/min<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. One study has showed that the presence of the
combination EOV and VE/VCO<sub>2</sub> &#x0003e; 34 is particularly more alarming because
of the risk for adverse cardiac events<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. Otherwise, our results do not agree
with the literature when it comes to the worst response of CET variables on EOV
population, described as lower peak VO<sub>2</sub>, higher VE/VCO<sub>2</sub> slope,
and lower rest and peak P<sub>ET</sub>CO<sub>2</sub>, when compared to non-EOV
population<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Hypotheses for these findings are the
heterogeneity of exercise protocols in the literature and the absence of a gold
standard to verify the presence of EOV in patients with profile and clinical status
similar to our subjects. In a meta-analysis about the assessment of EOV, Cornelis et
al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>
have suggested the use of Corr&#x000e0; et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> criteria, although none of the
criteria available appears to be superior. This criterion should be applied to a
constant load protocol since the VE data may not vary more than 15% compared to the
mean of rest VE data, which is a physiological response expected on the incremental
exercise protocol. Also, the presence of EOV may be longer than 60% of the exercise
time. For the results presented, we used Leite et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> criteria because these
are not so subjective since the presence of EOV is not calculated through time, but
as a continuous variation of the VE data with an waxing and waning pattern, and it
is not influenced by the time of its appearance, but by its amplitude. Finally, we
believe that Leite et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup> criteria could be more appropriate to assess EOV
during incremental exercise test.</p><p>Even though the trigger mechanisms of EOV are not totally understood, the main
hypotheses are circulatory delay, increased chemosensivity, increased ergoreflex
signaling, and/or pulmonary congestion<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. The reduced cardiac output leads to a
delayed lung-chemoreceptor circulation (peripheral/central); this and the
inefficient control of VE caused by increased chemosensitivity lead to an
exaggerated response of the ventilation<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. From the hemodynamic view, there is
an uncoupling on the right ventricle to lung circulation, and a pulmonary edema due
to a high ventricle filling pressure even when these patients are clinically stable
and on optimized drug therapy<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>.</p><p>Studies that evaluated the prognostic power of EOV obtained by the analysis of
ventilatory pattern of CHF patients when submitted to a CET suggest that this
variable seems to be the most important in the CET, even with better prognostic
values than VE/VCO<sub>2</sub> slope<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup>. Additionally, the presence of EOV combined
with higher values of VE/VCO<sub>2</sub>, mainly &#x0003e; 34, is even more alarming and
powerful to predict adverse cardiac events on CHF population<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>, characterizing that
these two ventilatory variables reflect the worst control on ventilation and
ventilatory inefficiency and may be translated into a better prognostic
definition<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>. In the present study, the comparison between
patients with EOV and VE/VCO<sub>2</sub> &#x0003e; 34 and patients with only one of these
showed no statistical difference on CET ventilatory variables, age, nor their
clinical status, such as LVEF. It is already known that the presence of EOV is not
altered by LVEF, since Guazzi et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup> showed no difference in incidence of EOV in CHF
patients with normal or reduced LVEF. It suggests the power of EOV as an independent
CET marker of worst prognostic because it represents the poor hemodynamic and
ventilatory adjust to physical exercise and did not correlate with other ventilatory
and metabolic CET variables with prognostic values.</p><p>Some studies focused on treatment of EOV and showed that the pathological pattern of
ventilation in EOV population can be modulated and even disappear. Three studies
evaluating pharmacological therapy with inodilator (malrinone)<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> and selective
pulmonary vasodilator (sildenafil)<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup> have shown some attenuation on EOV. In another
study based on aerobic training, for three months, 71% of the patients with stable
congestive heart failure showed a good EOV response<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>. These studies
evaluated stable patients on optimized drug therapy, which suggests that maybe EOV
does not respond to standard treatment for CHF, requiring other approaches than
pharmacological interventions, such as physical exercise.</p><p>Based on the present study's findings, it is important to encourage further studies
about EOV in CHF and other patients for a better comprehension of the role of EOV,
as well as to establish a gold standard pattern to verify the presence of this
variable in different diseases and levels of severity. Finally, this knowledge
improves therapeutic strategies.</p><sec><title>Limitations</title><p>The absence of gold standard in obtaining EOV must be considered, also some tool
to evaluate peripheral muscular strength would give information that could help
the interpretation of the findings. Results may not be extrapolated to more
severe patients. Finally, this study was made with a convenience sample and more
subjects should be recruited to consolidate our findings.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>The present study showed that there was an incidence of patients with EOV and lower
peak VO<sub>2</sub> and higher VE/VCO<sub>2</sub> slope values, but there was no
difference on other prognostic variables. In addition, no influence of the EOV
presence on other parameters of CET in this population was observed, suggesting that
this CET variable may be an independent marker of severity in CHF patients.</p><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">HVR</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PAS</td><td align="left" valign="top" rowspan="1" colspan="1">Final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">CLC</td><td align="left" valign="top" rowspan="1" colspan="1">Final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SG</td><td align="left" valign="top" rowspan="1" colspan="1">Final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JAN</td><td align="left" valign="top" rowspan="1" colspan="1">Final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ABS</td><td align="left" valign="top" rowspan="1" colspan="1">Final approval of the version to be
published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">MSR</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Research Group in Cardiorespiratory
Rehabilitation (GECARE) and the Department of Physical Therapy, Faculdade de
Medicina, Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ,
Brazil.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>Financial support: This study was supported by the Conselho Nacional de
Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico (CNPq) and the
Funda&#x000e7;&#x000e3;o Carlos Chagas Filho de Amparo &#x000e0; Pesquisa do Estado
do Rio de Janeiro (FAPERJ).</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dempsey</surname><given-names>JA</given-names></name><name><surname>Romer</surname><given-names>L</given-names></name><name><surname>Rodman</surname><given-names>J</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name></person-group><article-title>Consequences of exercise-induced respiratory muscle
work</article-title><source>Respir Physiol Neurobiol</source><year>2006</year><volume>151</volume><issue>2-3</issue><fpage>242</fpage><lpage>250</lpage><pub-id pub-id-type="pmid">16616716</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gosker</surname><given-names>HR</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>van der Vusse</surname><given-names>GJ</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name></person-group><article-title>Skeletal muscle dysfunction in chronic obstructive pulmonary
disease and chronic heart failure: underlying mechanisms and therapy
perspectives</article-title><source>Am J Clin Nutr</source><year>2000</year><volume>71</volume><issue>5</issue><fpage>1033</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">10799364</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahalin</surname><given-names>LP</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Guazzi</surname><given-names>M</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Cipriano</surname><given-names>G</given-names></name><name><surname>Chiappa</surname><given-names>G</given-names></name></person-group><article-title>Inspiratory muscle training in heart disease and heart failure: a
review of the literature with a focus on method of training and
outcomes</article-title><source>Expert Rev Cardiovasc Ther</source><year>2013</year><volume>11</volume><issue>2</issue><fpage>161</fpage><lpage>177</lpage><pub-id pub-id-type="pmid">23405838</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Izawa</surname><given-names>KP</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><name><surname>Osada</surname><given-names>N</given-names></name><name><surname>Kasahara</surname><given-names>Y</given-names></name><name><surname>Yokoyama</surname><given-names>H</given-names></name><name><surname>Hiraki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Handgrip strength as a predictor of prognosis in Japanese
patients with congestive heart failure</article-title><source>Eur J Cardiovasc Prev Rehabil</source><year>2009</year><volume>16</volume><issue>1</issue><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">19237993</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Guazzi</surname><given-names>M</given-names></name></person-group><article-title>The clinical and research applications of aerobic capacity and
ventilatory efficiency in heart failure: an evidence-based
review</article-title><source>Heart Fail Rev</source><year>2008</year><volume>13</volume><issue>2</issue><fpage>245</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">17987381</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibbons</surname><given-names>RJ</given-names></name><name><surname>Balady</surname><given-names>GJ</given-names></name><name><surname>Beasley</surname><given-names>JW</given-names></name><name><surname>Bricker</surname><given-names>JT</given-names></name><name><surname>Duvernoy</surname><given-names>WY</given-names></name><name><surname>Froelicher</surname><given-names>VF</given-names></name><etal/></person-group><article-title>ACC/AHA Guidelines for Exercise Testing. A report of the American
College of Cardiology/American Heart Association Task Force on Practice
Guidelines (Committee on Exercise Testing)</article-title><source>J Am Coll Cardiol</source><year>1997</year><volume>30</volume><issue>1</issue><fpage>260</fpage><lpage>311</lpage><pub-id pub-id-type="pmid">9207652</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poggio</surname><given-names>R</given-names></name><name><surname>Arazi</surname><given-names>HC</given-names></name><name><surname>Giorgi</surname><given-names>M</given-names></name><name><surname>Miriuka</surname><given-names>SG</given-names></name></person-group><article-title>Prediction of severe cardiovascular events by VE/VCO2 slope
versus peak VO2 in systolic heart failure: a meta-analysis of the published
literature</article-title><source>Am Heart J</source><year>2010</year><volume>160</volume><issue>6</issue><fpage>1004</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">21146651</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Aslam</surname><given-names>SS</given-names></name><name><surname>Varughese</surname><given-names>EB</given-names></name><name><surname>Peberdy</surname><given-names>MA</given-names></name></person-group><article-title>Peak VO2 and VE/VCO2 slope in patients with heart failure: a
prognostic comparison</article-title><source>Am Heart J</source><year>2004</year><volume>147</volume><issue>2</issue><fpage>354</fpage><lpage>360</lpage><pub-id pub-id-type="pmid">14760336</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahalin</surname><given-names>LP</given-names></name><name><surname>Chase</surname><given-names>P</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Bensimhon</surname><given-names>D</given-names></name><name><surname>Peberdy</surname><given-names>MA</given-names></name></person-group><article-title>A meta-analysis of the prognostic significance of cardiopulmonary
exercise testing in patients with heart failure</article-title><source>Heart Fail Rev</source><year>2013</year><volume>18</volume><issue>1</issue><fpage>79</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">22733204</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name><name><surname>Abella</surname><given-names>J</given-names></name><name><surname>Peberdy</surname><given-names>MA</given-names></name><name><surname>Pinkstaff</surname><given-names>S</given-names></name><name><surname>Bensimhon</surname><given-names>D</given-names></name><etal/></person-group><article-title>Prognostic value of timing and duration characteristics of
exercise oscillatory ventilation in patients with heart
failure</article-title><source>J Heart Lung Transplant</source><year>2008</year><volume>27</volume><issue>3</issue><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">18342759</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelis</surname><given-names>J</given-names></name><name><surname>Beckers</surname><given-names>P</given-names></name><name><surname>Vanroy</surname><given-names>C</given-names></name><name><surname>Volckaerts</surname><given-names>T</given-names></name><name><surname>Vrints</surname><given-names>C</given-names></name><name><surname>Vissers</surname><given-names>D</given-names></name></person-group><article-title>An overview of the applied definitions and diagnostic methods to
assess exercise oscillatory ventilation: a systematic review</article-title><source>Int J Cardiol</source><year>2015</year><volume>190</volume><fpage>161</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">25918072</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pauwels</surname><given-names>RA</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Jenkins</surname><given-names>CR</given-names></name><name><surname>Hurd</surname><given-names>SS</given-names></name><collab>GOLD Scientific Committee</collab></person-group><article-title>Global strategy for the diagnosis, management, and prevention of
chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for
Chronic Obstructive Lung Disease (GOLD) Workshop summary</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>163</volume><issue>5</issue><fpage>1256</fpage><lpage>1276</lpage><pub-id pub-id-type="pmid">11316667</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudson</surname><given-names>RJ</given-names></name><name><surname>Lebowitz</surname><given-names>MD</given-names></name><name><surname>Holberg</surname><given-names>CJ</given-names></name><name><surname>Burrows</surname><given-names>B</given-names></name></person-group><article-title>Changes in the normal maximal expiratory flow-volume curve with
growth and aging</article-title><source>Am Rev Respir Dis</source><year>1983</year><volume>127</volume><issue>6</issue><fpage>725</fpage><lpage>734</lpage><pub-id pub-id-type="pmid">6859656</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><article-title>Standardization of Spirometry, 1994 Update</article-title><person-group person-group-type="author"><collab>American Thoracic Society</collab></person-group><source>Am J Respir Crit Care Med</source><year>1995</year><volume>152</volume><issue>3</issue><fpage>1107</fpage><lpage>1136</lpage><pub-id pub-id-type="pmid">7663792</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leite</surname><given-names>JJ</given-names></name><name><surname>Mansur</surname><given-names>AJ</given-names></name><name><surname>Freitas</surname><given-names>HF</given-names></name><name><surname>Chizola</surname><given-names>PR</given-names></name><name><surname>Bocchi</surname><given-names>EA</given-names></name><name><surname>Terra-Filho</surname><given-names>M</given-names></name><etal/></person-group><article-title>Periodic breathing during incremental exercise predicts mortality
in patients with chronic heart failure evaluated for cardiac
transplantation</article-title><source>J Am Coll Cardiol</source><year>2003</year><volume>41</volume><issue>12</issue><fpage>2175</fpage><lpage>2181</lpage><pub-id pub-id-type="pmid">12821243</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Guazzi</surname><given-names>M</given-names></name><name><surname>Cahalin</surname><given-names>LP</given-names></name><name><surname>Myers</surname><given-names>J</given-names></name></person-group><article-title>Revisiting cardiopulmonary exercise testing applications in heart
failure: aligning evidence with clinical practice</article-title><source>Exerc Sport Sci Rev</source><year>2014</year><volume>42</volume><issue>4</issue><fpage>153</fpage><lpage>160</lpage><pub-id pub-id-type="pmid">25061999</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornelis</surname><given-names>J</given-names></name><name><surname>Taeymans</surname><given-names>J</given-names></name><name><surname>Hens</surname><given-names>W</given-names></name><name><surname>Beckers</surname><given-names>P</given-names></name><name><surname>Vrints</surname><given-names>C</given-names></name><name><surname>Vissers</surname><given-names>D</given-names></name></person-group><article-title>Prognostic respiratory parameters in heart failure patients with
and without exercise oscillatory ventilation: a systematic review and
descriptive meta-analysis</article-title><source>Int J Cardiol</source><year>2015</year><volume>182</volume><fpage>476</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">25616233</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guazzi</surname><given-names>M</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Ascione</surname><given-names>A</given-names></name><name><surname>Piepoli</surname><given-names>M</given-names></name><name><surname>Guazzi</surname><given-names>MD</given-names></name><collab>Gruppo di Studio Fisiologia dell'Esercizio, Cardiologia dello Sport
e Riabilitazione Cardiovascolare of the Italian Society of
Cardiology</collab></person-group><article-title>Exercise oscillatory breathing and increased ventilation to
carbon dioxide production slope in heart failure: an unfavorable combination
with high prognostic value</article-title><source>Am Heart J</source><year>2007</year><volume>153</volume><issue>5</issue><fpage>859</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">17452165</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corr&#x000e0;</surname><given-names>U</given-names></name><name><surname>Giordano</surname><given-names>A</given-names></name><name><surname>Bosimini</surname><given-names>E</given-names></name><name><surname>Mezzani</surname><given-names>A</given-names></name><name><surname>Piepoli</surname><given-names>M</given-names></name><name><surname>Coats</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Oscillatory ventilation during exercise in patients with chronic
heart failure: clinical correlates and prognostic
implications</article-title><source>Chest</source><year>2002</year><volume>121</volume><issue>5</issue><fpage>1572</fpage><lpage>1580</lpage><pub-id pub-id-type="pmid">12006446</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guazzi</surname><given-names>M</given-names></name></person-group><article-title>Abnormalities in cardiopulmonary exercise testing ventilatory
parameters in heart failure: pathophysiology and clinical
usefulness</article-title><source>Curr Heart Fail Rep</source><year>2014</year><volume>11</volume><issue>1</issue><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">24408786</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>XG</given-names></name><name><surname>Hansen</surname><given-names>JE</given-names></name><name><surname>Beshai</surname><given-names>JF</given-names></name><name><surname>Wasserman</surname><given-names>K</given-names></name></person-group><article-title>Oscillatory breathing and exercise gas exchange abnormalities
prognosticate early mortality and morbidity in heart failure</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>55</volume><issue>17</issue><fpage>1814</fpage><lpage>1823</lpage><pub-id pub-id-type="pmid">20413031</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guazzi</surname><given-names>M</given-names></name></person-group><article-title>Treating exercise oscillatory ventilation in heart failure: the
detail that may matter</article-title><source>Eur Respir J</source><year>2012</year><volume>40</volume><issue>5</issue><fpage>1075</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">23115310</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>JP</given-names></name><name><surname>Knutzen</surname><given-names>A</given-names></name><name><surname>Rocco</surname><given-names>MB</given-names></name><name><surname>Hartley</surname><given-names>LH</given-names></name><name><surname>Colucci</surname><given-names>WS</given-names></name></person-group><article-title>Periodic breathing during exercise in severe heart failure.
Reversal with milrinone or cardiac transplantation</article-title><source>Chest</source><year>1987</year><volume>92</volume><issue>3</issue><fpage>555</fpage><lpage>556</lpage><pub-id pub-id-type="pmid">3304852</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>RM</given-names></name><name><surname>Shah</surname><given-names>RV</given-names></name><name><surname>Malhotra</surname><given-names>R</given-names></name><name><surname>Pappagianopoulos</surname><given-names>PP</given-names></name><name><surname>Hough</surname><given-names>SS</given-names></name><name><surname>Systrom</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Exercise oscillatory ventilation in systolic heart failure: an
indicator of impaired hemodynamic response to exercise</article-title><source>Circulation</source><year>2011</year><volume>124</volume><issue>13</issue><fpage>1442</fpage><lpage>1451</lpage><pub-id pub-id-type="pmid">21875912</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zurek</surname><given-names>M</given-names></name><name><surname>Corr&#x000e0;</surname><given-names>U</given-names></name><name><surname>Piepoli</surname><given-names>MF</given-names></name><name><surname>Binder</surname><given-names>RK</given-names></name><name><surname>Saner</surname><given-names>H</given-names></name><name><surname>Schmid</surname><given-names>JP</given-names></name></person-group><article-title>Exercise training reverses exertional oscillatory ventilation in
heart failure patients</article-title><source>Eur Respir J</source><year>2012</year><volume>40</volume><issue>5</issue><fpage>1238</fpage><lpage>1244</lpage><pub-id pub-id-type="pmid">22408198</pub-id></element-citation></ref></ref-list></back></article>